The influence of estrogen on the development of the male reproductive system may be interrupted in a subset of Partial Androgen Insensitivity Syndrome (PAIS) patients. PAIS describes a wide range of male undermasculinisation resulting from mutations in the androgen receptor (AR) or steroid metabolism enzymes that perturb androgen-AR regulation of male sex organ development. In this study, we are interested in determining if PAIS-derived AR mutants that respond normally to androgen have altered responses to estrogen in the presence of ARA70, a coregulator previously shown to enhance E2-induced AR transactivation. The wild-type AR (wtAR), and two PAIS AR mutants, AR(S703G) and AR(E709K), all bind to androgen and E2 and subsequently translocate to the nucleus. While ARA70 functionally interacts with the wtAR and the PAIS AR mutants in response to androgen, E2 only promotes the functional interaction between ARA70 and the wtAR, but not the PAIS AR mutants. ARA70 increases E2 competitive-binding to the wtAR in the presence of low level androgen and also retards E2 dissociation from the wtAR. ARA70 is present in both the cytoplasm and the nucleus of various mouse testicular cells during early embryogenesis day 16 and Postpartum day 0 during estradiol synthesis and of the Leydig cells at Postpartum day 7 weeks. ARA70 may be unable to modulate the PAIS AR mutants-E2 binding, diminishing the effect of E2 via AR during male reproductive system development in patients with such mutations. Therefore, the presence of ARA70 in the testosterone and estrdiol-producing Leydig cells may enhance the overall activity of AR during critical stages of male sex organ development.
INTRODUCTION
Androgen action via the androgen receptor (AR) is critical in regulating male reproductive system development (1) . Insufficient androgen action may cause androgen insensitivity syndrome or male undermasculinised genitalia (2). The androgen insensitivity phenotypes vary from external genitalia that are completely female to degrees of partial masculinisation. The possible causes may range from mutations in the AR or 5α-reductase genes to abnormal levels of estrogen vs. androgen. While partial androgen insensitivity (PAIS)-associated AR mutations usually disrupt the response to androgen, a subset of patients has AR mutations without any apparent defect in androgen signaling (3, 4) .
Estrogen, primarily 17β-estradiol (E2), has also been proposed to be involved in both normal and abnormal processes of male reproductive development and associated diseases (5, 6) . Male estrogen is synthesized by aromatization of androgen, (e.g. testosterone), in many tissues including brain, liver, adipose tissue, and prostate (5). The physiological level of circulating E2 in the adult male is approximately 0.1 nM (73-184 pmol/L or 12-34 pg/ml), and in the adult female during pregnancy, the level of E2 is approximately 1 nM (367-1285 pmol/L or 100-350 pg/ml) (7) . However, local aromatase activity may cause particular tissue levels of E2 to be higher than the serum level.
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Based on reports using CV-1 (10, 11) or PC-3 (12) cells, it is possible that estrogen may influence male reproductive system development via the AR. Our previous report (13) demonstrated that E2-mediated wild type AR (wtAR) transactivation is enhanced by the addition of the AR coregulator ARA70, in DU145 cells. In HeLa cells, while E2 could promote the translocation of the wtAR from the cytoplasm to the nucleus, E2 requires selective coregulators, such as ARA70 or SRC-1, to induce significantly the wtAR transactivation (14). In PC-3 (15), CV-1 (16), and TSU-Pr1 (17) Therefore, certain coregulators may enable estrogen to influence AR target gene expression via the AR, and thereby potentially contribute to male sexual maturation.
Furthermore, there is evidence that the disruption of coactivators may also contribute to hormone resistance during target organ development (19) (20) (21) . Thus, certain PAISassociated AR mutations may disrupt this estrogen-dependent AR transactivation, modulated by coregulators, during male reproductive system development.
Here we have analyzed the functional interaction of PAIS-derived AR mutants with ARA70 in response to androgen or E2. Using co-immunoprecipitation and mammalian two-hybrid assays, we demonstrate that E2 promotes the interaction of ARA70 with the wtAR, but not with the PAIS mutants. By various ligand binding analyses, we also demonstrate that ARA70 increases the E2 competitive-binding to the wtAR at the low level of androgen and retards the dissociation of E2 from the wtAR-LBD, but not from the PAIS mutants. ARA70 is present in various fetal mouse testicular cells during early embryogenesis day 16 and Postpartum day 0 and is also significantly present in the Leydig cells at Postpartum day 7 weeks. ARA70 may therefore be unable The cells were then washed extensively with PBS and incubated in the presence or absence of a 10,000-fold molar excess of unlabeled R1881 or E2 (23, 24, 25 
RESULTS

ARA70 enhances the transactivation of wtAR, but not AR(S703G) or AR(E709K), in
response to E2-We used PCR site-directed mutagenesis to create several AR mutants based on mutations within the helix 3 region of the AR-LBD found in patients with complete or partial androgen-insensitivity (4). 
E2 can promote nuclear translocation of wtAR, AR(S703G) and AR(E709K) -We assayed the ability of AR(S703G) and AR(E709K) to translocate to the nucleus in response to E2
by immunocytofluorescence in COS-1 cells. As shown in Fig. 3A , in the absence of ligand, the wtAR and AR mutants are all localized in the cytoplasm. Addition of 10 nM DHT promoted the nuclear translocation of the wtAR, AR(S703G), and AR(E709K).
Addition of 10 nM E2 also promoted the nuclear translocation of the wtAR, AR(S703G), and AR(E709K) (Fig. 3B ). DAPI staining was used as a control for the location of the nuclei. Both E2 and DHT fail to bind to AR(N705S) and AR(L707R), and therefore cannot promote nuclear translocation of the receptors. 
ARA70 directly interacts with the wtAR in the presence of E2 by co-immunoprecipitation
assay-We have previously demonstrated that E2 induces an interaction between VP16-ARA70 and Gal4DBD-AR using a yeast two-hybrid system (13) . To confirm the direct E2-enhanced interaction between the wtAR and ARA70, we used a coimmunoprecipitation assay. Fig. 4A shows the direct E2-enhanced interaction of exogenous expressed wtAR and ARA70 in AR-negative COS-1 cells using an AR (NH27) antibody for co-immunoprecipitation, followed by Western blotting with AR and ARA70 antibodies. 
ARA70 does not interact with AR mutants in the presence of E2 by mammalian twohybrid assay-To
ARA70 influences the competitive-binding of E2 to the wtAR at the unsaturated androgen
levels-We next tested the influence of ARA70 on R1881 binding to the wtAR. Fig. 5A shows that the equilibrium binding constant, Kd, of R1881-wtAR in the presence or absence of co-expressed ARA70. Kds for wtAR and wtAR with ARA70 were 2.13±1.22 and 1.82±1.21 nM, respectively. These results indicate that under equilibrium conditions, ARA70 has no effect on R1881 binding to the wtAR. Given the high affinity of the wtAR for androgen, its cognate ligand, it is not surprising that ARA70 has no significant effect on wtAR-androgen binding.
Under physiological conditions where both androgen and estrogen are present, it is clear that the specificity and affinity of the wtAR for androgen, is far higher than that for estrogen. During development, however, maternal estrogen may influence the balance between androgen and estrogen in the developing fetus. Therefore, we tested whether ARA70 influences E2 competitive-binding to the AR in the presence of unsaturated levels of androgen (Fig. 5B Upper) We then tested the dissociation of [ (26, 27) , the AR staining was found in a small number of interstitial cells in the primordial mouse testis from embryonic day 15 to 16 (E15 to E16). The AR was not obviously expressed in the Sertoli cells until postnatal day 5 (26) . The AR was present in most cell types in the embryonic mouse testis at E16, and in germ cells and interstitial cells at Postpartum day 0 (P0) (27, 28) . The AR staining localized to the cytoplasm of Leydig cells in mouse testis at E16 and P0 (27) , which is in contrast to expression in the adult where staining was prominent in the nucleus (28) . The epithelium of the mesonephrosderived tissues, including the rete testis and the epididymis, exhibited a higher capacity to express the AR than did the rest of the testicular tissue (26) . Therefore, we determined whether ARA70 is localized with the AR during early embryogenesis, when estrogen is synthesized in the fetal testis. Mouse IgG was used as a negative control for staining (A, D and G). These data indicate that ARA70 expression begins in the Leydig cell, at the time of testosterone and E2 synthesis, during embryogenesis.
ARA70 is present in testicular Leydig cells during embryogenesis-In a previous reports
DISCUSSION
Androgen insensitivity syndrome is characterized by a spectrum of deficient male virilization or undermasculinization including testicular feminization (29) . It is known that if androgen action is slightly less than optimal, there will be undervirilization or inefficient spermatogenesis (29) . While mutation of the AR is often found in PAIS patients, certain mutations associated with PAIS respond normally to androgen (4). The first mutation analysed in this study, AR(S703G), was identified in a patient diagnosed with male pseudohermaphroditism which is associated with PAIS (3). The other mutation we studied, AR(E709K), is associated with Reifenstein syndrome (13) .
Reifenstein syndrome is a less severe variant of X-linked PAIS in which affected individuals present as phenotypic males with hypospadias, inadequate pubertal virilization, gynecomastia, and infertility (30). Our data in Figs. 5 and 6 show that ARA70 helps E2 competitively bind to the wtAR and subsequently retards E2 dissociation from the wtAR binding pocket. This phenomenon may be important during the prenatal period (7) where high maternal estrogen levels may initiate estrogen signaling via the wtAR in the presence of coregulators, such as ARA70. For example, one report found that plasma concentrations of testosterone and E2 in mothers delivering male babies were 1.2±0. 4 and 4.5±0.7 ng/ml, respectively (31), and these sex hormone levels may influence the balance between androgens and estrogens in the male fetus. Studies of 20 fetal rat testis samples collected during genital tract differentiation (gestation) also reported that there is a negligible level of circulating DHT in fetal rat plasma (32) . In addition, male and female rat fetuses had similar plasma levels of DHT and E2, although male fetuses did have higher levels of testosterone (32) . High aromatase activity during the last days of fetal life may also convert testosterone to E2 in male fetuses (32, 33) , further altering the balance of these sex hormones. Therefore, while male sexual differentiation and reproductive organ development are critically dependent on androgen-AR signaling, it is possible that estrogen-AR-coregulator signaling may influence androgen action in conditions where DHT levels are negligible and testosterone is readily aromatized to estrogen. The loss of the E2-AR-coregulator pathway may partly disrupt the balance between AR and ER signaling during critical stages in male reproductive system development. Fig. 4B demonstrates that the S703G and E709K PAIS mutants cannot functionally interact with ARA70 in response to E2. Therefore, decreased total receptor activity in AR(S703G) and AR(E709K) PAIS patients may tip the balance in favor of ER signaling, resulting in undermasculinization.
Our in vivo data in Fig. 8 shows that ARA70 and the AR are both present in the interstitial cells of the mouse E16 testis. Primitive sex cords mature to form testis cords and the rete testis at 13 days post coitum (34) . By 15 days, the vas deferens, epididymis and seminal vesicles arise from the Wolffian duct and the testis develops prominent sex cords, each of which become a seminiferous tubule (34) . At this point, the cord contains uniform but undifferentiated cells, which are precursors of spermatogenic or Sertoli cells.
As the testis continues to develop, mesenchymal cells between the testis cords become 
